CNSP - CIK 0001729427
The table below shows CNS Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $3.54M | $2.20M | $1.17M | $3.24M | $4.24M | $1.12M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.43M |
| $1.06M |
| $1.24M |
| $1.09M |
| $1.38M |
| $1.41M |
| Operating income | -$4.98M | -$3.25M | -$2.41M | -$4.34M | -$5.63M | -$2.53M |
| Income tax | - | - | - | - | - | - |
| Net income | -$4.94M | -$3.22M | -$2.37M | -$4.30M | -$5.61M | -$2.53M |
| EPS (diluted) | -$7.30 | -$5.76 | -$6.42 | -$18.93 | -$153.20 | -$4.05K |